U
GNMX

UBS’s Aevi Genomic Medicine Inc GNMX Stock Holding History

UBS’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$1K Sell
200
-3,800
-95% -$24.5K ﹤0.01% 10216
2014
Q2 		$31K Sell
4,000
-144
-3% -$1.02K ﹤0.01% 7525
2014
Q1 		$29K Buy
4,144
+144
+4% +$1.13K ﹤0.01% 7607
2013
Q4 		$24K Buy
4,000
+3,166
+380% +$20.7K ﹤0.01% 7932
2013
Q3 		$7K Buy
+834
New +$3.87K ﹤0.01% 9173

Other funds holding GNMX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

UBS's GNMX Position: Q3 2014 in Review

UBS reduced its Aevi Genomic Medicine Inc (GNMX) stake by 95% in Q3 2014, selling an estimated $24.5K and leaving 200 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #10216.

UBS first reported a position in GNMX in Q3 2013 and has held it in 5 quarters since. The position peaked at $31K in Q2 2014. 24 funds tracked by Wall St. Rank hold GNMX as of Q3 2014.

  • UBS held 200 shares of Aevi Genomic Medicine Inc worth $1K as of Q3 2014.
  • UBS sold 3,800 Aevi Genomic Medicine Inc shares in Q3 2014, an estimated $24.5K.
  • Aevi Genomic Medicine Inc made up ﹤0.01% of UBS's portfolio in Q3 2014, its #10216 holding.
  • UBS first reported a position in Aevi Genomic Medicine Inc in Q3 2013 and has held it in 5 quarters since.
  • UBS's Aevi Genomic Medicine Inc position peaked at $31K in Q2 2014.
  • 24 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.